The Food and Drug Administration (FDA) continues to report shortages of GE Healthcare’s Omnipaque™ (iohexol) and iodixanol intravenous contrast media products for computed tomography imaging. In an April 19, 2022, letter to customers, GE Healthcare said it was rationing orders for its iohexol products after a COVID-19 lockdown temporarily shut down its production facility for iodinated contrast media in Shanghai, China.
Knowledge Center
Filter your results: